ADMA Biologics (NASDAQ:ADMA) Receives Overweight Rating from Cantor Fitzgerald

ADMA Biologics (NASDAQ:ADMA)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $25.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 80.92% from the company’s previous close.

A number of other equities analysts have also weighed in on the stock. HC Wainwright upped their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James upped their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Stock Down 12.7 %

ADMA Biologics stock opened at $13.82 on Tuesday. The company has a 50 day moving average of $16.69 and a 200-day moving average of $17.98. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics has a twelve month low of $5.52 and a twelve month high of $23.64. The stock has a market capitalization of $3.27 billion, a PE ratio of 48.93 and a beta of 0.75.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in ADMA Biologics by 1.3% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock worth $865,000 after buying an additional 645 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock valued at $954,000 after acquiring an additional 700 shares during the last quarter. Summit Investment Advisors Inc. raised its holdings in ADMA Biologics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company’s stock worth $404,000 after acquiring an additional 746 shares in the last quarter. Mutual of America Capital Management LLC raised its holdings in ADMA Biologics by 2.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock worth $614,000 after acquiring an additional 751 shares in the last quarter. Finally, Maryland State Retirement & Pension System boosted its position in ADMA Biologics by 1.1% during the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock valued at $1,365,000 after purchasing an additional 897 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.